AstraZeneca R&D leader Pangalos warns of a post-Brexit UK research retreat without reimbursement reform
AstraZeneca’s influential R&D leader Mene Pangalos has blasted the UK government’s drug watchdog NICE for keeping the price of new drugs at low levels, saying that regulators are threatening the industry’s substantial R&D presence in the country in a post-Brexit world.
“To continue to get the research and investment here, you have to pay for the drugs,” Pangalos told The Telegraph in an interview. “Research and adoption of clinical innovation go hand in hand and the Government has to be prepared to pay for treatments that work.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.